Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Lakewood-Amedex Biotherapeutics, Inc.
Market Cap
$1.45M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.47M
EBITDA Margin
-346.64%
TTM Avg
-376.56%
3Y Avg
-438.06%
5Y Avg
-395.70%
Market Cap
$1.45M
EBITDA Margin
-75.46%
TTM Avg
-92.89%
3Y Avg
-421.55%
5Y Avg
-389.33%
Market Cap
$1.47M
EBITDA Margin
-1231.39%
TTM Avg
-651.84%
3Y Avg
-512.06%
5Y Avg
-24032.93%
Market Cap
$1.21M
EBITDA Margin
-17.60%
TTM Avg
-16.25%
3Y Avg
-23.94%
5Y Avg
-32.10%
Market Cap
$1.17M
EBITDA Margin
-40873.19%
TTM Avg
-40873.19%
3Y Avg
-21172.28%
5Y Avg
-10780.34%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lakewood-Amedex Biotherapeutics, Inc. (LABT) | $1.45M | N/A | N/A | N/A | N/A |
| Curis, Inc. (CRIS)vs › | $1.47M | -346.64% | -376.56% | -438.06% | -395.70% |
| INVO Fertility, Inc. (IVF)vs › | $1.45M | -75.46% | -92.89% | -421.55% | -389.33% |
| PMGC Holdings Inc. (ELAB)vs › | $1.47M | -1231.39% | -651.84% | -512.06% | -24032.93% |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.40M | N/A | N/A | N/A | N/A |
| NewcelX Ltd. (NCEL)vs › | $1.37M | N/A | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.32M | N/A | N/A | N/A | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.21M | -17.60% | -16.25% | -23.94% | -32.10% |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.17M | -40873.19% | -40873.19% | -21172.28% | -10780.34% |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.11M | -6.76% | -0.42% | 7.09% | 7.09% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
